TSXV - Delayed Quote CAD

MedMira Inc. (MIR.V)

0.1300

0.0000

(0.00%)

At close: January 10 at 3:01:33 PM EST

MedMira Receives Investigational Testing Authorization for its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test

HALIFAX, NS / ACCESSWIRE / January 9, 2025 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announced that its received investigational testing authorization (ITA) from Health Canada to begin clinical trials for its Multiplo® Complete Syphilis (TP/nTP) ...

ACCESSWIRE yesterday

MMIRF
MedMira Reports First Quarter Results FY2025

HALIFAX, NS / ACCESSWIRE / December 30, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended October 31, 2024. Corporate update During Q1 FY2025, MedMira has been continuing its regulatory work and ...

ACCESSWIRE 11 days ago

MMIRF
Health Canada approves MedMira’s rapid test for HIV and syphilis

The test enables healthcare professionals to identify HIV-1/2 and syphilis antibodies from a single finger prick sample.

Medical Device Network 15 days ago

MMIRF
TSX Venture Exchange Stock Maintenance Bulletins

TSX VENTURE COMPANIES

CNW Group 17 days ago

CBUTF

WWTIF

MMIRF
MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV

HALIFAX, NS / ACCESSWIRE / December 24, 2024 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today, on December 24, 2024, the approval from Health Canada for its Multiplo® Rapid TP/HIV Test (Multiplo® TP/HIV) to be rolled ...

ACCESSWIRE 17 days ago

MMIRF
MedMira Reports FY2024 Fourth Quarter and Year End Financial Results

HALIFAX, NS / ACCESSWIRE / November 28, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the financial year ended July 31, 2024. Corporate Update In December 2023, the Company received the 510(k) (FDA) approval ...

ACCESSWIRE last month

MMIRF
MedMira Announces the appointment of Vice President of Commercial Operations

MedMira Inc. continues its North-American expansion plan HALIFAX, NS / ACCESSWIRE / October 3, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) today announced the appointment of Nicole Crenshaw as Vice President of Commercial Operations, effective ...

ACCESSWIRE 3 months ago

MMIRF
Clinical Trials to get Underway with Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test - A Potential Game Changer to Address Syphilis Health Crisis in Canada

HALIFAX, NS / ACCESSWIRE / August 13, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announces it will conduct full clinical trials for its unique Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP) with the goal of getting it licensed ...

ACCESSWIRE 4 months ago

MMIRF
MedMira Reports Third Quarter Results FY2024

HALIFAX, NS / ACCESSWIRE / July 2, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended April 30, 2024. Corporate update In Q3 FY2024, MedMira focused on the launch of MedMira's latest US FDA approved ...

ACCESSWIRE 6 months ago

MMIRF
MedMira Announces the Hire of Vice President of Business Development

HALIFAX, NS / ACCESSWIRE / April 30, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to announce the expansion of their commercialisation team by welcoming Ms. Rene Bell to the position of Vice President of Business Development. Ms. Bell ...

ACCESSWIRE 8 months ago

MMIRF
MedMira Second Quarter 2024 Earnings: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2023)

MedMira ( CVE:MIR ) Second Quarter 2024 Results Key Financial Results Revenue: CA$148.7k (down 13% from 2Q 2023). Net...

Simply Wall St. 9 months ago

MMIRF
MedMira Reports Second Quarter Results FY2024

HALIFAX, NS / ACCESSWIRE / April 1, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2024. Corporate update During Q2 FY2024, MedMira received the US FDA 510(k) clearance for the HIV-2 ...

ACCESSWIRE 9 months ago

MMIRF
MedMira Receives Canadian Patent for its Unique Quantitative Diagnostic System

HALIFAX, NS / ACCESSWIRE / March 13, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announces the receipt of a Canadian patent patent (number 2,949,634) for its new innovative and quantitative test system. This is in addition to the U.S. patent (number ...

ACCESSWIRE 9 months ago

MMIRF
CORRECTION BY SOURCE: Corporate Update on Clinical Evaluation of MedMira's Products

Correction: Extended clarification. HALIFAX, NS / ACCESSWIRE / February 1, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to provide an update on the ongoing review process by Health Canada. The Company made the submission and since then ...

ACCESSWIRE 11 months ago

MMIRF
Corporate Update on Clinical Evaluation of MedMira’s Products

HALIFAX, NS / ACCESSWIRE / February 1, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to provide an update on the ongoing review process by Health Canada. The Company made the required submission and has been working towards extending ...

ACCESSWIRE 11 months ago

MMIRF

Performance Overview

Return	MIR.V	S&P/TSX Composite index
YTD	+18.18%	+0.60%
1-Year	+18.18%	+18.10%
3-Year	-50.00%	+17.47%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

MedMira Inc. (MIR.V)

MedMira Receives Investigational Testing Authorization for its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test

MedMira Reports First Quarter Results FY2025

Health Canada approves MedMira’s rapid test for HIV and syphilis

TSX Venture Exchange Stock Maintenance Bulletins

MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV

MedMira Reports FY2024 Fourth Quarter and Year End Financial Results

MedMira Announces the appointment of Vice President of Commercial Operations

Clinical Trials to get Underway with Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test - A Potential Game Changer to Address Syphilis Health Crisis in Canada

MedMira Reports Third Quarter Results FY2024

MedMira Announces the Hire of Vice President of Business Development

MedMira Second Quarter 2024 Earnings: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2023)

MedMira Reports Second Quarter Results FY2024

MedMira Receives Canadian Patent for its Unique Quantitative Diagnostic System

CORRECTION BY SOURCE: Corporate Update on Clinical Evaluation of MedMira's Products

Corporate Update on Clinical Evaluation of MedMira’s Products

Performance Overview